- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | AstraZeneca, Daiichi celebrate another recommended approval of Enhertu | 19 | Alliance News | ||
| Fr | Daiichi Sankyo: Enhertu Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer | 588 | Business Wire | Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
Daiichi Sankyo and AstraZeneca's... ► Artikel lesen | |
| Do | Astra-Daiichi breast cancer drug Enhertu recommended for NHS use in England | 3 | Seeking Alpha | ||
| Do | IHH Unit Fortis Files Supreme Court Against Delhi High Court Order In Daiichi Proceedings | 2 | BusinessToday | ||
| Mi | Daiichi and AstraZeneca cancer drugs secure further approvals in Japan | 8 | Alliance News | ||
| 14.09. | AstraZeneca, Daiichi report Enhertu benefit in advanced lung cancer | 8 | Alliance News | ||
| 14.09. | Tokyo Court rejects IHH unit's claims against Daiichi Sankyo | 18 | Singapore Business Review | ||
| 11.09. | Fierce Pharma Asia-Takeda's R&D leadership change; Daiichi's $1.3B court win; New Samsung Bio contract | 10 | FiercePharma | ||
| DAIICHI SANKYO CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 10.09. | Tokyo Court Dismisses NTK's ¥203bn Damages Claim Against Daiichi Sankyo | 4 | Tokyo Brief | ||
| 10.09. | IHH unit loses ¥200 bil damages claim against Daiichi Sankyo | 5 | The Edge Markets | ||
| 10.09. | IHH Healthcare Unit Loses Daiichi Sankyo Court Claim In Japan, Ordered To Bear Litigation Costs | 4 | BusinessToday | ||
| 04.09. | Daiichi unit American Regent recalls 3 epinephrine batches on particulate, leakage concerns | 10 | FiercePharma | ||
| 01.09. | Astra, Daiichi granted EU nod for Enhertu in first-line breast cancer | 10 | Seeking Alpha | ||
| 01.09. | AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer | 3 | PMLiVE | ||
| 01.09. | EU lässt Brustkrebsmedikament von Astrazeneca und Daiichi Sankyo zu | 656 | Dow Jones News | DJ EU lässt Brustkrebsmedikament von Astrazeneca und Daiichi Sankyo zu
Von Adria Calatayud
DOW JONES--Astrazeneca und Daiichi Sankyo haben von der Europäischen Union die Zulassung für eine... ► Artikel lesen | |
| 01.09. | Enhertu von AstraZeneca und Daiichi Sankyo erhält EU-Zulassung für die Erstlinienbehandlung von HER2-positivem Brustkrebs | 8 | Investing.com Deutsch | ||
| 01.09. | Daiichi Sankyo: Enhertu Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | 551 | Business Wire | Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca's Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP... ► Artikel lesen | |
| 01.09. | Indian court directs forensic auditor appointment in Daiichi-Fortis case, IHH says | 12 | The Edge Markets | ||
| 28.08. | New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk | 590 | Business Wire | Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction... ► Artikel lesen | |
| 26.08. | IN BRIEF: Daiichi Sankyo, AstraZeneca start phase 3 Datroway trial | 6 | Alliance News |
1 2 3 4 5 Weiter >>
136 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,100 | +0,27 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| GILEAD SCIENCES | 131,60 | +0,75 % | Dividendenbekanntmachungen (15.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKVA GROUP ASA NO0003097503 1 NOK 0,0927 EUR ALEXANDRIA GROUP OYJ FI4000153465 - 0,35 EUR ALTRIA GROUP INC US02209S1033 1,11 USD 0... ► Artikel lesen | |
| VIATRIS | 14,950 | -1,09 % | Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? | ||
| BIONANO GENOMICS | 1,840 | +7,29 % | Bionano highlights studies showing OGM utility in blood cancers | ||
| JAZZ PHARMACEUTICALS | 213,70 | +1,91 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences | Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy
Transaction strengthens Jazz's epilepsy pipeline... ► Artikel lesen | |
| DAIICHI SANKYO | 16,516 | +1,44 % | Daiichi Sankyo: Enhertu Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer | Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
Daiichi Sankyo and AstraZeneca's... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 6,900 | 0,00 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 463,10 | +0,09 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| OPUS GENETICS | 4,480 | -0,44 % | Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? | ||
| SAVARA | 4,631 | +0,32 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,980 | +2,58 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine | Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic... ► Artikel lesen | |
| BIOHAVEN | 12,025 | +1,48 % | Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing... ► Artikel lesen | |
| SKYE BIOSCIENCE | 1,510 | +10,22 % | XFRA NEW INSTRUMENTS AVAILABLE ON 24.08.2026 | The following instruments on XETRA do have their first trading 24.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.08.2026
Aktien
1 CA0966311064 Boardwalk Real Estate... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY | 1,320 | -1,12 % | MAIA Biotechnology, Inc.: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial | Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million... ► Artikel lesen | |
| BAYER | 49,030 | -1,94 % | Bayer, BASF und Allianz: Aktuelle Kursziele und eine Sonderchance | Bayer, BASF und Allianz gehören zu den prominentesten deutschen DAX-Konzernen und stehen derzeit erneut im Fokus der Anleger. Ein Blick auf die aktuellen Analysten-Kursziele zeigt, wie unterschiedlich... ► Artikel lesen |
DAIICHI SANKYO CO LTD ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 15,700 Euro und damit +0,64 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAIICHI SANKYO CO LTD ADR finden Sie auf Wallstreet Online.